接受免疫疗法治疗的东亚患者在晚期非小细胞肺癌中获得了改善的生存益处:更新的元分析
Yueyuan Yao1,2, Butuo Li2, Yiyue Xu2
1Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Cancer medicine
|March 8, 2024
概括
与非东亚 (nEA) 患者相比,接受免疫检查点抑制剂 (ICI) 的非小细胞肺癌 (NSCLC) 的东亚 (EA) 患者的生存结果有所改善. 建议对EA NSCLC患者进行早期干预和联合治疗,特别是使用PD-1抑制剂.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 与化疗相结合的免疫检查点抑制剂 (ICI) 是没有驱动突变的高级NSCLC的标准.
- 瘤遗传学的种族差异可能会影响东亚 (EA) 和非东亚 (nEA) 人口之间的ICI疗效.
- 关于ICI疗效的种族差异的先前研究已经产生了不一致的结果.
研究的目的:
- 为了比较EA中的ICI临床结果与NSCLC的nEA患者.
- 调查ICI对NSCLC治疗疗效的种族差异.
主要方法:
- 一项对21项随机对照试验 (RCT) 的元分析,涉及9826名NSCLC患者 (4064名EA).
- 评估整体生存期 (OS) 和无进展生存期 (PFS).
- 根据治疗线路,组合与单疗法以及ICI类型 (PD-1,PD-L1,CTLA-4抑制剂) 的亚组分析.
主要成果:
- 与非EA患者相比,接受ICI的EA NSCLC患者的生存状况明显改善 (p=0.02).
- 第一线ICI和化疗-ICI治疗在EA患者中显示出优异的OS和PFS益处.
- 与PD-L1抑制剂相比,PD-1抑制剂在EA和nEA患者中改善了OS.
结论:
- 与nEA患者相比,EA NSCLC患者从基于ICI的治疗中显著受益.
- 建议在EA NSCLC患者早期使用ICI和组合治疗.
- PD-1 抑制剂与EA和nEA群体的延长存活率有关.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K